Kolon Pharma’s plaque psoriasis treatment 'Skilarence Enteric Coated Tab. (Dimethyl fumarate)' will be reimbursed if the company accepts a price lower than the price assessed by the Pharmaceutical Benefit Assessment Committee.

On the 8th, the National Health Insurance Service (President Sun-min Kim) disclosed the deliberation results on the adequacy of medical care benefit for pharmaceuticals that applied for decisions at the ‘2021 9th PBAC meeting.’

Skilarence is a treatment for adult patients with moderate-to-severe plaque psoriasis in adults subject to systemic or light therapy. The drug received marketing authorization on May 14th.